All In Biotech

Drug Trial Radar · NCT07491172

A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias

A Phase 1 Open-label, Multicenter, First-in-human, Ascending Dose Trial Evaluating the Safety and Tolerability of a Lipid Nanoparticle Formulation of CRISPR-Guide RNA-Cas9 Nuclease (CTX310) for In Vivo Editing of the Angiopoietin-like 3 (ANGPTL3) Gene in Participants With Refractory Dyslipidemias

Last checked: Nov 20, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Jun 21, 2024

Primary completion

Jun 2027

Study completion Jun 2028

Sponsor

Lead sponsor
CRISPR Therapeutics AGIndustry
Sponsor type
Industry
First posted
Mar 24, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single-arm, open-label, multicenter, ascending dose Phase 1 trial that will enroll participants 18 to 75 years of age with dyslipidemias that are refractory to available treatments.

Conditions

  • Cardiovascular
  • Metabolic Disease
  • Dyslipidemias
  • Lipid Disorder
  • Hypertriglyceridemia
  • Heterozygous Familial Hypercholesterolemia (HeFH)
  • Homozygous Familial Hypercholesterolemia (HoFH)
  • Severe Hypertriglyceridemia (sHTG)
  • Mixed Hyperlipemia
  • Hypercholesterolaemia

Interventions

  • CTX310Drug

    CTX310 is a lipid nanoparticle (LNP) formulation of clustered regularly interspaced short palindromic repeats (CRISPR)-associated protein 9 (Cas9) components for in vivo editing of the target gene angiopoietin-like 3 (ANGPTL3).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the safety of CTX310 in adult subjects with dyslipidemias that are refractory to available treatmentsTime frame: From CTX310 infusion up to 12 months

Locations

17 sites in 4 countries. Site status is shown where the registry gives one.

  • Integrity Clinical Research

    Hialeah, Florida · Recruiting

  • Jacksonville Center for Clinical Research

    Jacksonville, Florida · Recruiting

  • Flourish Orlando

    Orlando, Florida · Recruiting

  • United Medical Research

    Port Orange, Florida · Recruiting

  • University of Rochester

    Rochester, New York · Recruiting

  • Duke Early Phase Clinical Research

    Durham, North Carolina · Recruiting

  • Peters Medical Research

    High Point, North Carolina · Recruiting

  • Oregon Health & Science University (OHSU)

    Portland, Oregon · Recruiting

  • Royal Adelaide

    Adelaide, Australia · Recruiting

  • CORE Research

    Brisbane, Australia · Recruiting

  • Royal Prince Alfred Hospital

    Camperdown, Australia · Not yet recruiting

  • Austin Health

    Heidelberg, Australia · Recruiting

  • Monash Medical Center

    Melbourne, Australia · Recruiting

  • Aotearoa

    Auckland, New Zealand · Recruiting

  • NZCR

    Christchurch, New Zealand · Recruiting

  • Royal Papworth Hospital

    Cambridge, United Kingdom · Recruiting

  • Richmond Pharmacology

    London, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.